A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration

Cell Death and Differentiation

Volumn 22, Issue 5, 2015, Pages 731-742

  Di Stefano, M ^a   Nascimento Ferreira, I ^b   Orsomando, G ^c   Mori, V ^c   Gilley, J ^b   Brown, R ^d   Janeckova, L ^b   Vargas, M E ^e,f   Worrell, L A ^b   Loreto, A ^a   Tickle, J ^a   Patrick, J ^b   Webster, J R M ^a   Marangoni, M ^a   Carpi, F M ^g   Pucciarelli, S ^g   Rossi, F ^a   Meng, W ^a   Sagasti, A ^f   Ribchester, R R ^d   Magni, G ^g   Coleman, M P ^b   Conforti, L ^a   more..

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e JULES STEIN EYE INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; BACTERIAL PROTEIN; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE; NICOTINAMIDENUCLEOTIDE AMIDASE; NMNAT2 PROTEIN, MOUSE;

ANIMAL; AXON; GENETICS; METABOLISM; MOUSE; NERVE DEGENERATION; PATHOLOGY; PERIPHERAL NERVE INJURIES;

AMIDOHYDROLASES; ANIMALS; AXONS; BACTERIAL PROTEINS; MICE; NERVE DEGENERATION; NICOTINAMIDE MONONUCLEOTIDE; NICOTINAMIDE-NUCLEOTIDE ADENYLYLTRANSFERASE; PERIPHERAL NERVE INJURIES;

EID: 84936993267     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.164     Document Type: Article

References (64)

1. Stoll G, Jander S, Myers RR. Degeneration and regeneration of the peripheral nervous system: from Augustus Waller's observations to neuroinflammation. J Peripher Nerv Syst 2002; 7: 13-27.
2. Lunn ER, Perry VH, Brown MC, Rosen H, Gordon S. Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve. Eur J Neurosci 1989; 1: 27-33.
3. Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci 2014; 15: 394-409.
4. Agostini M, Bedin C, Pucciarelli S, Enzo M, Briarava M, Seraglia R et al. APC I1307K mutations and forkhead box gene (FOXO1A): another piece of an interesting correlation. Int J Biol Markers 2012; 27: 13-19.
5. Martin SM, O'Brien GS, Portera-Cailliau C, Sagasti A. Wallerian degeneration of zebrafish trigeminal axons in the skin is required for regeneration and developmental pruning. Development 2010; 137: 3985-3994.
6. Adalbert R, Gillingwater TH, Haley JE, Bridge K, Beirowski B, Berek L et al. A rat model of slowWallerian degeneration (WldS) with improved preservation of neuromuscular synapses. Eur J Neurosci 2005; 21: 271-277.
7. MacDonald JM, Beach MG, Porpiglia E, Sheehan AE, Watts RJ, Freeman MR et al. The Drosophila cell corpse engulfment receptor Draper mediates glial clearance of severed axons. Neuron 2006; 50: 869-881.
8. Kitay BM, McCormack R, Wang Y, Tsoulfas P, Zhai RG. Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLDS-mediated axon protection independent of axonal mitochondria. Hum Mol Genet 2013; 22: 1601-1614.
9. Conforti L, Tarlton A, Mack TG, Mi W, Buckmaster EA, Wagner D et al. A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proc Natl Acad Sci USA 2000; 97: 11377-11382.
10. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 2001; 4: 1199-1206.
11. Koch-Nolte F, Fischer S, Haag F, Ziegler M. Compartmentation of NAD+-dependent signalling. FEBS Lett 2011; 585: 1651-1656.
12. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 2005; 280: 36334-36341.
13. Conforti L, Wilbrey A, Morreale G, Janeckova L, Beirowski B, Adalbert R et al. Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice. J Cell Biol 2009; 184: 491-500.
14. Beirowski B, Babetto E, Gilley J, Mazzola F, Conforti L, Janeckova L et al. Non-nuclear Wld (S) determines its neuroprotective efficacy for axons and synapses in vivo. J Neurosci 2009; 29: 653-668.
15. Avery MA, Sheehan AE, Kerr KS, Wang J, Freeman MR. Wld S requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration. J Cell Biol 2009; 184: 501-513.
16. Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol 2010; 8: e1000300.
17. Hicks AN, Lorenzetti D, Gilley J, Lu B, Andersson KE, Miligan C et al. Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) regulates axon integrity in the mouse embryo. PLoS One 2012; 7: e47869.
18. Gilley J, Adalbert R, Yu G, Coleman MP. Rescue of peripheral and CNS axon defects in mice lacking NMNAT2. J Neurosci 2013; 33: 13410-13424.
19. Milde S, Gilley J, Coleman MP. Subcellular localization determines the stability and axon protective capacity of axon survival factor Nmnat2. PLoS Biol 2013; 11: e1001539.
20. Babetto E, Beirowski B, Russler EV, Milbrandt J, Diantonio A. The phr1 ubiquitin ligase promotes injury-induced axon self-destruction. Cell Rep 2013; 3: 1422-1429.
21. Xiong X, Hao Y, Sun K, Li J, Li X, Mishra B et al. The highwire ubiquitin ligase promotes axonal degeneration by tuning levels of nmnat protein. PLoS Biol 2012; 10: e1001440.
22. Yahata N, Yuasa S, Araki T. Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci 2009; 29: 6276-6284.
23. Avery MA, Rooney TM, Pandya JD, Wishart TM, Gillingwater TH, Geddes JW et al. WldS prevents axon degeneration through increased mitochondrial flux and enhanced mitochondrial Ca2+ buffering. Curr Biol 2012; 22: 596-600.
24. Barrientos SA, Martinez NW, Yoo S, Jara JS, Zamorano S, Hetz C et al. Axonal degeneration is mediated by the mitochondrial permeability transition pore. J Neurosci 2011; 31: 966-978.
25. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305: 1010-1013.
26. Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW et al. A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 2005; 170: 349-355.
27. Conforti L, Fang G, Beirowski B, Wang MS, Sorci L, Asress S et al. NAD(+) and axon degeneration revisited: Nmnat1 cannot substitute forWld(S) to delayWallerian degeneration. Cell Death Differ 2007; 14: 116-127.
28. Sasaki Y, Vohra BP, Lund FE, Milbrandt J. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci 2009; 29: 5525-5535.
29. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003; 63: 7436-7442.
30. Billington RA, Genazzani AA, Travelli C, Condorelli F. NAD depletion by FK866 induces autophagy. Autophagy 2008; 4: 385-387.
31. Billington RA, Travelli C, Ercolano E, Galli U, Roman CB, Grolla AA et al. Characterization of NAD uptake in mammalian cells. J Biol Chem 2008; 283: 6367-6374.
32. Watson M, Roulston A, Bélec L, Billot X, Marcellus R, Bédard D et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 2009; 29: 5872-5888.
33. Nikiforov A, Dolle C, Niere M, Ziegler M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem 2011; 286: 21767-21778.
34. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci 2007; 32: 12-19.
35. Garavaglia S, Bruzzone S, Cassani C, Canella L, Allegrone G, Sturla L et al. The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism. Biochem J 2012; 441: 131-141.
36. Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, Brenner C et al. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 2007; 129: 473-484.
37. Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 2005; 6: 889-898.
38. Wang M, Wu Y, Culver DG, Glass JD. The gene for slow Wallerian degeneration (Wld(s)) is also protective against vincristine neuropathy. Neurobiol Dis 2001; 8: 155-161.
39. Galeazzi L, Bocci P, Amici A, Brunetti L, Ruggieri S, Romine M et al. Identification of nicotinamide mononucleotide deamidase of the bacterial pyridine nucleotide cycle reveals a novel broadly conserved amidohydrolase family. J Biol Chem 2011; 286: 40365-40375.
40. Beirowski B, Berek L, Adalbert R, Wagner D, Grumme DS, Addicks K et al. Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFPH mice. J Neurosci Methods 2004; 134: 23-35.
41. Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 2009; 77: 1612-1620.
42. Vincent A, Briggs L, Chatwin GF, Emery E, Tomlins R, Oswald M et al. 2012 parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress. Hum Mol Genet 21: 1760-1769.
43. Natera-Naranjo O, Kar AN, Aschrafi A, Gervasi NM, Macgibeny MA, Gioio AE et al. Local translation of ATP synthase subunit 9 mRNA alters ATP levels and the production of ROS in the axon. Mol Cell Neurosci 2012; 49: 263-270.
44. Shen H, Hyrc KL, Goldberg MP. Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection. Neurobiol Dis 2013; 59: 69-79.
45. Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F et al. Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem 2010; 285: 34106-34114.
46. Bi J, Li H, Ye SQ, Ding S. Pre-B-cell colony-enhancing factor exerts a neuronal protection through its enzymatic activity and the reduction of mitochondrial dysfunction in in vitro ischemic models. J Neurochem 2012; 120: 334-346.
47. Wang P, Xu TY, Guan YF, Tian WW, Viollet B, Rui YC et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol 2011; 69: 360-374.
48. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011; 14: 528-536.
49. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L et al. Declining NAD (+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 2013; 155: 1624-1638.
50. Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 2012; 337: 481-484.
51. Bhattacharya MR, Gerdts J, Naylor SA, Royse EX, Ebstein SY, Sasaki Y et al. A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration. J Neurosci 2012; 32: 5054-5061.
52. Coleman MP, Freeman MR. Wallerian degeneration, Wld(s), and NMNAT. Annu Rev Neurosci 2010; 33: 245-267.
53. Olesen UH, Christensen MK, Björkling F, Jäättelä M, Jensen PB, Sehested M et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008; 367: 799-804.
54. Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 2012; 70: 18-25.
55. Miledi R, Slater CR. On the degeneration of rat neuromuscular junctions after nerve section. J Physiol 1970; 207: 507-528.
56. Coleman MP, Perry VH. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 2002; 25: 532-537.
57. Raff MC, Whitmore AV, Finn JT. Axonal self-destruction and neurodegeneration. Science 2002; 296: 868-871.
58. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000; 28: 41-51.
59. Buckmaster EA, Perry VH, Brown MC. The rate of Wallerian degeneration in cultured neurons from wild type and C57BL/WldS mice depends on time in culture and may be extended in the presence of elevated K+ levels. Eur J Neurosci 1995; 7: 1596-1602.
60. Balducci E, Emanuelli M, Raffaelli N, Ruggieri S, Amici A, Magni G et al. Assay methods for nicotinamide mononucleotide adenylyltransferase of wide applicability. Anal Biochem 1995; 228: 64-68.
61. Ribchester RR, Tsao JW, Barry JA, Asgari-Jirhandeh N, Perry VH, Brown MC et al. Persistence of neuromuscular junctions after axotomy in mice with slow Wallerian degeneration (C57BL/WldS). Eur J Neurosci 1995; 7: 1641-1650.
62. Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM et al. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci 2004; 20: 3092-3114.
63. O'Brien GS, Martin SM, Söllner C, Wright GJ, Becker CG, Portera-Cailliau C et al. Developmentally regulated impediments to skin reinnervation by injured peripheral sensory axon terminals. Curr Biol 2009; 19: 2086-2090.
64. Gillingwater TH, Thomson D, Mack TG, Soffin EM, Mattison RJ, Coleman MP et al. Agedependent synapse withdrawal at axotomised neuromuscular junctions in Wld(s) mutant and Ube4b/Nmnat transgenic mice. J Physiol 2002; 543(Pt 3): 739-755.